Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
convalescent plasma anti-SARS-CoV-2 immunoglobulins
- Development stage
- Unknown
- Lead developer
- Erasmus MC
- Administration
- Intravenous
01
Overview
Convalescent plasma anti-SARS-CoV-2 immunoglobulins (COVIg) is a biologic therapy consisting of concentrated, purified virus-neutralizing antibodies (polyclonal immunoglobulins) derived from the plasma of individuals who have recovered from COVID-19. Developed by Erasmus MC in the Netherlands, the product is designed for passive immunization, specifically targeting the SARS-CoV-2 spike protein to neutralize the virus and inhibit its replication. It has been primarily investigated for the treatment and prevention of COVID-19 in immunocompromised patients, such as those with primary or secondary immunodeficiencies who fail to mount an adequate response to active vaccination. The preparation is concentrated to provide a higher titer of neutralizing antibodies compared to standard convalescent plasma.
- Other names
- hyperimmune anti-SARS-CoV-2 immunoglobulinsanti-SARS-CoV-2 hyperimmune globulinanti-SARS-CoV2 hyperimmune globulinanti-SARS-CoV 2 hyperimmune globulinhyperimmune anti-SARS-CoV-2 immunoglobulin
02
Targets
FcγR/C1q (Host Fc gamma receptors and complement component C1q)SARS-CoV-2 spike
Beyond the preview
Go deeper on convalescent plasma anti-SARS-CoV-2 immunoglobulins.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on convalescent plasma anti-SARS-CoV-2 immunoglobulins.